In this phase 3 trial involving patients with high-risk diffuse large B-cell lymphoma, addition of tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival compared to R-CHOP alone, with a 25% reduction in risk of progression or death and an 8.2% absolute increase in 2-year PFS rates. Event-free survival was also improved, though overall survival data remain immature and not significantly different. The combination was associated with higher rates of hematologic and infectious adverse events, including fatal events, but did not impair delivery of R-CHOP.
Study
|
Phase 3, randomised, double-blind, placebo-controlled global trial [frontMIND] |
| Previously untreated high-intermediate-risk or high-risk DLBCL or high-grade B-cell lymphoma |
| Tafasitamab plus lenalidomide and R-CHOP (n=448) versus R-CHOP (n=451) for six 21-day cycles
|
Efficacy
|
ORR: 80.4% vs 76.1% (Tafa-Len + R-CHOP vs. R-CHOP alone) (OR 1.29 [0.94-1.78]) |
| 3-year PFS: 67.3% vs 60.7% (HR 0.75 [0.59-0.96]; p=0.0194) |
| 3-year EFS: 61.2% vs 54.8% (HR 0.79 [0.64-0.97]; p=0.0260) |
| 3-year OS: 81.1% vs 77.8% (HR 0.85 [0.63-1.14])
|
Safety
|
Grade >=3 AE: neutropenia (69% vs 58%), thrombocytopenia (27% vs 14%), anaemia (24% vs 16%), febrile neutropenia (16% vs 13%) |
| Serious TRAEs: 50% vs 39% |
| Fatal TRAEs: 6% vs 4%
|
Lancet. Published online May 30, 2026
http://doi.org/10.1016/S0140-6736(26)00866-4
Reviewed by Ulas D. Bayraktar, MD on Jun 14, 2026
